An announcement from Jazz Pharmaceuticals ( (JAZZ) ) is now available.
On March 4, 2025, Jazz Pharmaceuticals announced a merger agreement to acquire Chimerix for $8.55 per share, totaling approximately $935 million. This acquisition will enhance Jazz’s oncology portfolio by adding dordaviprone, a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The transaction, approved by both companies, is expected to close in the second quarter of 2025. Dordaviprone, which has shown promising clinical trial results, is under FDA review for accelerated approval. The acquisition is anticipated to strengthen Jazz’s presence in the rare oncology space and provide a significant commercial opportunity, potentially making dordaviprone a standard of care for this rare disease.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing life-changing medicines for serious diseases, including sleep disorders, epilepsy, and cancer. The company is headquartered in Dublin, Ireland, and has a diverse portfolio of marketed medicines and a robust pipeline of innovative therapeutics in oncology and neuroscience.
YTD Price Performance: 12.27%
Average Trading Volume: 699,099
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.44B
See more data about JAZZ stock on TipRanks’ Stock Analysis page.